Last reviewed · How we verify
NCT03600311: RIDE
Resistance Exercise and Protein During Weight Loss
NA trial testing Caloric Restriction in Weight Loss in 17 participants. Completed in 31 May 2019.
1 May 2019
Quick facts
| Lead sponsor | University of Nebraska Lincoln |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 17 |
| Start date | 31 August 2018 |
| Primary completion | 1 May 2019 |
| Estimated completion | 31 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Caloric Restriction
- Post-Exercise Protein
- Energy Balance
- Post-Exercise Carbohydrate
- Calcium and Vitamin D
Conditions studied
- Weight Loss — all drugs for Weight Loss →
- Starvation — all drugs for Starvation →
Sponsor
University of Nebraska Lincoln
Who can join
Adults 19 to 30, any sex, with Weight Loss or Starvation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if post-exercise protein supplementation can rescue the anabolic response of muscle and bone to resistance exercise during caloric restriction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Caloric restriction induces anabolic resistance to resistance exercise.
Murphy C, Koehler K. · · 2020 · cited 25× · PMID 32236752 · DOI 10.1007/s00421-020-04354-0
Verify or expand the search:
- PubMed search for NCT03600311
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Caloric Restriction
Trials testing the same drug.
- NCT05499702 — The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction · Phase 2 · recruiting
- NCT05076357 — Cold, Appetite and Weight Loss in Individuals With Obesity · NA · unknown
- NCT03669692 — Open Randomized Clinical Trial to Evaluate the Effects of Intermittent Caloric Restriction in Patients With Lower Urinar · NA · withdrawn
- NCT01083108 — Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Met · Phase 2 · terminated
Other recruiting trials for Weight Loss
Currently open trials in the same condition.
- NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
- NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
- NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
- NCT06785064 — Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance · NA · recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other University of Nebraska Lincoln trials
Trials by the same sponsor.
- NCT07160530 — Healthy Children, Healthy Communities: Effectiveness of a Multilevel Rural Community Engagement Model for Improving Chil · NA · recruiting
- NCT06935435 — Effects of Distinct Nebraska-Dry Bean Market Classes on Gut Microbiota · NA · active not recruiting
- NCT05873413 — Motivations, Attitudes, and Perceptions Study · NA · recruiting
- NCT05988398 — Preventing Commercial Sexual Exploitation of Children · NA · completed
- NCT05791825 — Evaluation of the CHIME Intervention for Improving Early Head Start/Head Start Educator Well-being · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03600311 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Nebraska Lincoln
- Last refreshed: 12 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03600311.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing